Sun Pharma ANZ

10 PBAC submissions on file, active 2018–2025. 70% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Abiraterone acetate and methylprednisolone
  Oncology · Recommended with restriction · 2023—
• Tildrakizumab
  Dermatology · Recommended with restriction · 2023—
• Adrenaline
  Immunology · Deferred · 2018other sponsor
• Cetrorelix
  Women's health · Recommended · 2025—
• Ciclosporin
  Ophthalmology · Recommended with restriction · 2022—
• Sonidegib
  Dermatology · Noted · 2023other sponsor
• Teriparatide
  Endocrinology · Recommended · 2025—

Therapy area mix

Activity by year

2018 (2) · 2022 (3) · 2023 (3) · 2025 (2)

Rejection patterns

Across 2 Not recommended decisions on file.

• 1×Insufficient comparative evidence versus infliximab and ixekizumab
• 1×non-inferiority to ustekinumab not supported by indirect comparisons
• 1×potential inferiority to ustekinumab 90mg
• 1×no demonstrated significant clinical benefit over currently listed biologics
• 1×no clinical need for a seventh biological agent for chronic plaque psoriasis